Pembrolizumab (KEYTRUDA (R)) in Combination with Axitinib (Inlyta (R)) for First-line Treatment of advanced Renal Cell Cancer Death Risk under Pembrolizumab Combination is almost halved Compared to Sunitinib-MedSci.cn

Pembrolizumab (KEYTRUDA (R)) in Combination with Axitinib (Inlyta (R)) for First-line Treatment of advanced Renal Cell Cancer Death Risk under Pembrolizumab Combination is almost halved Compared to Sunitinib

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2019; 42 (4): 233

科室
- - 订阅+
  - 更多科室
工具
服务